CHIARLE, Roberto
CHIARLE, Roberto
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC)
2012-01-01 C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle
CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation
2005-01-01 Boccalatte F; Piva R; Manazza A; Palestro G; Chiarle R; Inghirami G
Conditional expression of activated met in differentiated skeletal muscle induces atrophy
2006-01-01 CREPALDI T.; BERSANI F.; SCUOPPO C.; ACCORNERO P.; PRUNOTTO C.; TAULLI R.; FORNI P.; LEO C.; CHIARLE R.; GRIFFITHS J.; GLASS D.; PONZETTO C.
Constitutively active Stat3 triggers the development of autoimmune myocarditis
2009-01-01 Camporeale A; Marino F; Brero A; Chiarle R; Jensen O; Levi R; Poli V
Constitutively active STAT3 triggers the development of autoimmune myocarditis
2009-01-01 Camporeale A; Marino F; Brero A; Chiarle R; Jensen O; Levi R; Poli V
Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation
2007-01-01 Piva R; E Pellegrino; V Grosso; AD Manazza; F Boccalatte; V Poli; A Neri; R Chiarle; G Inghirami
Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity
2007-01-01 Piva R; Pellegrino E; Chiarle R; Manazza AD; Boccalatte F; Neri A; Levy DE; Inghirami G
DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer.
2011-01-01 Paola Cappello; Simona Rolla; Roberta Curto; Helen Carnevale; Roberto Chiarle; Federica Cavallo; Mirella Giovarelli; Francesco Novelli
Efficacy of DNA vaccination against Anaplastic Lymphoma Kinase (ALK) in Non Small Cell Lunger carcinoma (NSCLC)
2011-01-01 C. Voena; C. Mastini; M. Menotti; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; G. Inghirami; R. Chiarle
Espressione delle Heat Shock Proteins nella nefropatia diabetica sperimentale
2008-01-01 Pinach S; Barutta F; Forbes J; Chiarle R; Giunti S; Arnstein M; Miceli I; Cavallo Perin P; Camussi G; Cooper ME; Gruden G
Expression of angiogenesis-related biomarkers in thymic epithelial tumors (TET).
2010-01-01 Marino M; Lattanzio R; Lauriola L; Martucci R; Sioletic S; Gallo E; Palmieri G; Evoli A; Granone P; Palestro G; Chiarle R; Barreca A; Pich A; Remotti D; Pisa R; Martelli M; Truini M; Ascani S; Ruco L; Rendina EA; Tunesi G; Antimi M; Lalle M; Carlini S; Facciolo F; Piantelli M.
Heat shock protein expression in early diabetic nephropathy
2007-01-01 Barutta F; Pinach S; Forbes J; Chiarle R; Giunti S; Arnstein M; Cavallo Perin P; Camussi G; Cooper ME; Gruden G.
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA
2005-01-01 R Piva; E Pellegrino; M Mattioli; C Voena; C Conte; F Boccalatte; C Ambrogio; A Manazza; A Neri; R Chiarle; G Inghirami
In T lymphocytes, ablation of STAT3 expression reinstates STAT1-dependent apoptosis by both IFNg and IL-6
2006-01-01 Regis G; Icardi L; Conti L; Chiarle R; Bernabei P; Poli V; Novelli F.
In the absence of Insulin-like Growth Factor (IGF)-1 signaling, Interferon-gamma (IFN-g) inhibits the growth of human malignant T cells
2006-01-01 Conti L; Longo A; Regis G; Giovarelli M; Chiarle R; Novelli F.
Molecola perturbation of IFNγR2 internalization reinstates T cell sensitività to the IFNγ/STAT1 signaling pathway in vitro and in vivo. 5th
2007-01-01 Boselli D; Ragimbeau J; Orlando L; Cappello P; Bernabei P; Ambrogio C; Chiarle R; Pellegrini S; Giovarelli M; Novelli F.
p53 overexpression and thymoma prognosis
1996-01-01 PICH A; CHIARLE R; CHIUSA L; MOTTA M; PALESTRO G
p53 overexpression, DNA ploidy and cell proliferative activity are prognostic factors in stage I-II thymomas
1995-01-01 PICH A; CHIARLE R; CHIUSA L; PONTI R; GEUNA M; PALESTRO G
Parametri biologici di malignità nei linfomi di piccole cellule CD5 positivi
1998-01-01 PALESTRO G; PONTI R; CHIUSA L; CHIARLE R; GEUNA M; NOVERO D; PAGANO M; PICH A
Prognostic value of AgNORs in tumour pathology
1996-01-01 PICH A; CHIUSA L; CHIARLE R; MARGARIA E
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC) | 2012 | C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle | |
| CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation | 2005 | Boccalatte F; Piva R; Manazza A; Palestro G; Chiarle R; Inghirami G | |
| Conditional expression of activated met in differentiated skeletal muscle induces atrophy | 2006 | CREPALDI T.; BERSANI F.; SCUOPPO C.; ACCORNERO P.; PRUNOTTO C.; TAULLI R.; FORNI P.; LEO C.; CHIARLE R.; GRIFFITHS J.; GLASS D.; PONZETTO C. | |
| Constitutively active Stat3 triggers the development of autoimmune myocarditis | 2009 | Camporeale A; Marino F; Brero A; Chiarle R; Jensen O; Levi R; Poli V | |
| Constitutively active STAT3 triggers the development of autoimmune myocarditis | 2009 | Camporeale A; Marino F; Brero A; Chiarle R; Jensen O; Levi R; Poli V | |
| Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation | 2007 | Piva R; E Pellegrino; V Grosso; AD Manazza; F Boccalatte; V Poli; A Neri; R Chiarle; G Inghirami | |
| Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity | 2007 | Piva R; Pellegrino E; Chiarle R; Manazza AD; Boccalatte F; Neri A; Levy DE; Inghirami G | |
| DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer. | 2011 | Paola Cappello; Simona Rolla; Roberta Curto; Helen Carnevale; Roberto Chiarle; Federica Cavallo; Mirella Giovarelli; Francesco Novelli | |
| Efficacy of DNA vaccination against Anaplastic Lymphoma Kinase (ALK) in Non Small Cell Lunger carcinoma (NSCLC) | 2011 | C. Voena; C. Mastini; M. Menotti; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; G. Inghirami; R. Chiarle | |
| Espressione delle Heat Shock Proteins nella nefropatia diabetica sperimentale | 2008 | Pinach S; Barutta F; Forbes J; Chiarle R; Giunti S; Arnstein M; Miceli I; Cavallo Perin P; Camussi G; Cooper ME; Gruden G | |
| Expression of angiogenesis-related biomarkers in thymic epithelial tumors (TET). | 2010 | Marino M; Lattanzio R; Lauriola L; Martucci R; Sioletic S; Gallo E; Palmieri G; Evoli A; Granone P; Palestro G; Chiarle R; Barreca A; Pich A; Remotti D; Pisa R; Martelli M; Truini M; Ascani S; Ruco L; Rendina EA; Tunesi G; Antimi M; Lalle M; Carlini S; Facciolo F; Piantelli M. | |
| Heat shock protein expression in early diabetic nephropathy | 2007 | Barutta F; Pinach S; Forbes J; Chiarle R; Giunti S; Arnstein M; Cavallo Perin P; Camussi G; Cooper ME; Gruden G. | |
| Identification of genomic and proteomic signatures in lymphomas by inducible shRNA | 2005 | R Piva; E Pellegrino; M Mattioli; C Voena; C Conte; F Boccalatte; C Ambrogio; A Manazza; A Neri; R Chiarle; G Inghirami | |
| In T lymphocytes, ablation of STAT3 expression reinstates STAT1-dependent apoptosis by both IFNg and IL-6 | 2006 | Regis G; Icardi L; Conti L; Chiarle R; Bernabei P; Poli V; Novelli F. | |
| In the absence of Insulin-like Growth Factor (IGF)-1 signaling, Interferon-gamma (IFN-g) inhibits the growth of human malignant T cells | 2006 | Conti L; Longo A; Regis G; Giovarelli M; Chiarle R; Novelli F. | |
| Molecola perturbation of IFNγR2 internalization reinstates T cell sensitività to the IFNγ/STAT1 signaling pathway in vitro and in vivo. 5th | 2007 | Boselli D; Ragimbeau J; Orlando L; Cappello P; Bernabei P; Ambrogio C; Chiarle R; Pellegrini S; Giovarelli M; Novelli F. | |
| p53 overexpression and thymoma prognosis | 1996 | PICH A; CHIARLE R; CHIUSA L; MOTTA M; PALESTRO G | |
| p53 overexpression, DNA ploidy and cell proliferative activity are prognostic factors in stage I-II thymomas | 1995 | PICH A; CHIARLE R; CHIUSA L; PONTI R; GEUNA M; PALESTRO G | |
| Parametri biologici di malignità nei linfomi di piccole cellule CD5 positivi | 1998 | PALESTRO G; PONTI R; CHIUSA L; CHIARLE R; GEUNA M; NOVERO D; PAGANO M; PICH A | |
| Prognostic value of AgNORs in tumour pathology | 1996 | PICH A; CHIUSA L; CHIARLE R; MARGARIA E |